News

Tiffany Braley, MD, MS, associate professor of neurology, University of Michigan, provided insight on the challenges of fatigue in multiple sclerosis, and where research efforts should be directed to.

In recognition of World MS Day, Meghan Beier, PhD, MA, a health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine, discussed the effects of multiple sclerosis (MS) on cognitive function.

The research, which highlighted stressors occurring in both childhood and adult stages contributing to MS disability, could inform conversations regarding stress reduction techniques for patients with MS.

In recognition of World MS Day, the health and rehabilitation psychologist at the Rowan Center for Behavioral Medicine discussed types of interventions for managing cognitive changes in patients with multiple sclerosis. [WATCH TIME: 5 minutes]

Kathy Zackowski, PhD, OTR, associate vice president of research at the National MS Society, provided insight on the ongoing efforts to treat progressive MS, including strategies to develop remyelinating treatments.

On multiple phase 3 trials, treatment with STS101 resulted in numerical differences on primary outcome measures of pain freedom and freedom from the most bothersome symptoms.

The medical director of SleepMed in South Carolina discussed the need for more overall awareness of poor sleep and the risk factors associated with worsened heart health. [WATCH TIME: 3 minutes]

Pitolisant, a therapy approved for patients with narcolepsy, is currently being assessed in 200 individuals with idiopathic hypersomnia, with change in excessive daytime sleepiness as the primary outcome.

Here's some of what is coming soon to NeurologyLive® this week.

As part of our monthly clinician spotlight, NeurologyLive® highlighted stroke expert Andrew Russman, DO, head of the Stroke Program and medical director of the Comprehensive Stroke Center at Cleveland Clinic.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is Alzheimer disease and dementia.

Over a 72-week treatment period, vatiquinone showed significant impacts on bulbar and upright stability subscales of the modified Friedreich Ataxia Rating Scale score.

The clinical professor in the Department of Neurology at the University of California, San Francisco, talked about the association between contaminated water and Parkinson disease. [WATCH TIME: 6 minutes]

Investigators observed similar rates of intracranial hemorrhage for patients with minor stroke on a dual thrombolytic treatment vs those who received alteplase alone.

Neurology News Network for the week ending May 27, 2023. [WATCH TIME: 3 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 26, 2023.

The director of the Memory & Cognitive Disorders Clinic at Hoag Neuroscience Institute provided perspective on the difficulties with testing agents for Parkinson disease psychosis, and the future outlook of treating the symptom. [WATCH TIME: 4 minutes]

In a 6-month trial, more than 85% of adults on CBD showed significant reduction in the number of monthly seizures, suggesting this treatment may be an effective adjuvant option.

Fifty-four percent of patients with ALS carried at least one detrimental common variant or repeat expansion, highlighting the clinical impact of gene variants as modifiers in ALS.

Thirty days after treatment, a primary-outcome event occurred in 2.9% of those in the early-treatment group and 4.1% of those in the later-treatment group.

Study shows that digital devices can provide objective and real-world measures of Parkinson disease, capturing key motor and nonmotor features of for early diagnosis of the neurodegenerative disorder.

The director of vascular neurology at NYU Langone Hospital in Brooklyn discussed the high prevalence of common risk factors for stroke, emphasizing the importance of early detection and management for prevention. [WATCH TIME: 4 minutes]

Poststroke patients who engaged in at least 4 hours of physical activity per week had a higher likelihood of a mild stroke and had smaller hematoma volumes on admission.

The associate professor at the University of Colorado highlighted the limitations of standard care visits in collecting crucial data from pediatric multiple sclerosis centers. [WATCH TIME: 3 minutes]

Using trials selected by amyloid positivity, amyloid-targeting therapies had slightly greater efficacy in APOE ε4 carriers than in noncarriers.

Robust, sustained reductions in key pharmacodynamic biomarker were observed; however, this did not lead to functional benefits on any of the scales used in the trial.

The head of CRCSEP and coordinator of the Neurosciences Research Unit at Paris City University discussed the positive results of teriflunomide in treating radiologically isolated syndrome, a preclinical stage of multiple sclerosis. [WATCH TIME: 4 minutes]

Submitted under the accelerated approval pathway, if approved, SRP-9001 would become the first marketed gene therapy specific for Duchenne muscular dystrophy.

The director of the James J. and Joan A. Gardner Family Center discussed data from the phase 3 BouNDless trial assessing a continuous, subcutaneous levodopa/carbidopa delivery system for patients with Parkinson disease experiencing motor fluctuations. [WATCH TIME: 3 minutes]

The senior associate consultant in the Department of Neurology at Mayo Clinic provided insight on an early feasibility study on the clinical impact of microburst vagus nerve stimulation in patients with drug-resistant epilepsy.